Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

NCT05241392 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

BIOLOGICAL: B7-H3-targeting CAR-T cells

Sponsor

Beijing Tiantan Hospital